Krsnaa Diagnostics Limited (KRSNAA) AI Stock Analysis

• Market Cap: ₹26.05B
• Dividend Yield: 0.31%
• Average Volume (3M): 7.30K
• Price to Earnings (P/E): 32.3
• Beta (1Y): 0.96
• Revenue Growth: 13.78%
• EPS Growth: 32.19%
• Country: IN
• Employees: 3,700
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 6.38
• Shares Outstanding: 32,438,670
• 10 Day Avg. Volume: 6,020
• 30 Day Avg. Volume: 7,302
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹868.00
• Price Target Upside: 0.04% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: ₹851.00 ▼(-1.92% Downside)

Krsnaa Diagnostics Limited shows strong financial performance with robust revenue growth and a solid balance sheet. However, the stock faces challenges with free cash flow generation and appears overvalued based on its P/E ratio. Technical indicators provide mixed signals, with the stock trading below key moving averages.

Krsnaa Diagnostics Limited Business Overview & Revenue Model

Company Description

Krsnaa Diagnostics Limited (KRSNAA) is a leading diagnostics service provider in India, specializing in a broad range of diagnostic services including imaging, pathology, and tele-radiology. The company is recognized for its extensive network of diagnostic centers and its strategic partnerships with public health agencies to provide accessible and affordable diagnostic services across various regions, particularly in underserved areas.

How the Company Makes Money

Krsnaa Diagnostics Limited makes money primarily through the provision of diagnostic services, which include imaging, pathology, and tele-radiology. The company generates revenue by establishing diagnostic centers through public-private partnerships with government hospitals and agencies, providing outsourced diagnostic services. Additionally, KRSNAA earns income from direct payments by private patients who utilize their diagnostic services. The company leverages its extensive network and strategic partnerships to expand its reach and service offerings, thus contributing significantly to its revenue streams.

Krsnaa Diagnostics Limited Financial Statement Overview

Summary

Krsnaa Diagnostics Limited exhibits strong financial performance with robust revenue growth and a high gross profit margin. The balance sheet is solid with low financial leverage and a strong equity position. However, challenges in free cash flow generation present a potential risk, although operating cash flows remain stable.

Income Statement

Krsnaa Diagnostics Limited shows strong revenue growth with a notable increase of 15.74% from 2024 to 2025. The company maintains a substantial gross profit margin of 76.38% for 2025, reflecting efficient cost management. However, while the net profit margin improved to 10.82%, there is room for enhancement in profitability metrics such as EBIT and EBITDA margins, which stand at 14.19% and 26.51% respectively. Overall, the income statement indicates a solid performance with positive growth trends.

Balance Sheet

The balance sheet of Krsnaa Diagnostics Limited is quite robust, with a healthy equity ratio of 68.87%, indicating a strong equity position relative to total assets. The debt-to-equity ratio at 0.23 suggests low financial leverage, which is a positive sign for financial stability. Additionally, the return on equity (ROE) is 8.79%, showing decent returns for shareholders. The balance sheet reflects sound financial management with a strong equity base and controlled leverage.

Cash Flow

The cash flow statement reveals challenges in free cash flow generation, with a negative free cash flow of -393 million in 2025, albeit an improvement from the previous year. The operating cash flow to net income ratio of 1.13 is solid, indicating good cash conversion efficiency. However, the company has faced difficulties in managing capital expenditures, which impacts free cash flow. Overall, while operating cash flows are stable, the negative free cash flow presents a potential risk area to address.

Breakdown	Mar 2025	Mar 2024	Mar 2022	Mar 2023	Mar 2021
Income Statement
Total Revenue	7.17B	6.20B	4.55B	4.87B	3.96B
Gross Profit	5.48B	2.05B	3.95B	4.13B	3.13B
EBITDA	1.90B	1.61B	1.46B	1.42B	3.59B
Net Income	776.08M	568.37M	683.88M	621.11M	1.85B
Balance Sheet
Total Assets	12.82B	11.72B	8.76B	9.10B	6.05B
Cash, Cash Equivalents and Short-Term Investments	684.36M	535.45M	2.54B	1.21B	1.53B
Total Debt	2.04B	1.60B	349.84M	324.81M	2.32B
Total Liabilities	3.99B	3.62B	2.07B	1.71B	3.73B
Stockholders Equity	8.83B	8.10B	6.69B	7.39B	2.32B
Cash Flow
Free Cash Flow	-393.00M	-1.70B	-37.95M	-650.59M	357.18M
Operating Cash Flow	873.27M	243.45M	1.28B	763.01M	1.03B
Investing Cash Flow	-996.09M	-1.29B	-2.41B	-1.09B	-611.39M
Financing Cash Flow	137.53M	841.87M	1.76B	-331.45M	308.40M

Krsnaa Diagnostics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 867.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRSNAA, the sentiment is Negative. The current price of 867.65 is above the 20-day moving average (MA) of 843.68, above the 50-day MA of 769.78, and above the 200-day MA of 804.78, indicating a neutral trend. The MACD of 13.28 indicates Positive momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 33.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KRSNAA.

Krsnaa Diagnostics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LALPATHLAB	70 Outperform	₹272.57B	52.84		0.73%	10.57%	34.11%
VIJAYA	66 Neutral	₹107.71B	71.70		0.10%	22.34%	20.75%
METROPOLIS	64 Neutral	₹108.55B	70.98		0.71%	12.86%	10.42%
KRSNAA	63 Neutral	₹26.05B	32.35		0.31%	13.78%	32.19%
HCG	61 Neutral	₹93.53B	252.00		―	16.85%	-29.52%
MEDICAMEQ	54 Neutral	₹4.83B	51.18		0.28%	-9.35%	-17.40%
Sector *	51 Neutral	kr6.00B	8.78	-28.70%	2.24%	51.61%	19.20%

Krsnaa Diagnostics Limited Corporate Events

Krsnaa Diagnostics Releases Q1 2025 Financial Results

Krsnaa Diagnostics Limited announced the publication of its unaudited financial results for the quarter ending June 30, 2025, in prominent newspapers such as Financial Express and Loksatta. This disclosure is part of the company’s compliance with SEBI regulations, reflecting its commitment to transparency and providing stakeholders with timely financial information.

Krsnaa Diagnostics Releases Q1 FY2026 Financial Results

Krsnaa Diagnostics Limited has released an investor presentation detailing its unaudited financial results for the quarter ending June 30, 2025. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic positioning in the diagnostic services industry.